%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Pontali, E.
%A Raviglione, M. C.
%A Migliori, G. B.
%A Akkerman, O. W.
%A Alffenaar, J. W.
%A Blanc, F. X.
%A Borisov, S.
%A Cirillo, D. M.
%A Dalcolmo, M.
%A Dheda, K.
%A Kritski, A. L.
%A Lienhardt, Christian
%A Olliaro, P.
%A Tadolini, M.
%A Tiberi, S.
%A Udwadia, Z.
%A Global T. B. Network Clinical Trials,
%T Regimens to treat multidrug-resistant tuberculosis : past, present and future perspectives
%D 2019
%L PAR00019680
%G ENG
%J European Respiratory Review
%@ 0905-9180
%M ISI:000477993000003
%N 152
%P art. 190035 [7 ]
%R 10.1183/16000617.0035-2019
%U https://www.documentation.ird.fr/hor/PAR00019680
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers19-08/010076505.pdf
%V 28
%W Horizon (IRD)
%X Over the past few decades, treatment of multidrug-resistant (MDR)/ extensively drugresistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 2024 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases. World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9-10 months. The objectives of this article are to review the main achievements in MDR-TB treatment through the description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant TB.
%$ 050